Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ole Kirk

Showing results (121-130 of 171) with videos related to

Pageof 18
Sort By:
AIDS (London, England)|October 14, 2017
Abacavir use and risk of recurrent myocardial infarctionCaroline A Sabin, Lene Ryom, Antonella d'Arminio Monforte, et al.
Journal of the International AIDS Society|November 14, 2014
Major challenges in clinical management of TB/HIV co-infected patients in Eastern Europe compared with Western Europe and Latin AmericaAnne Marie Efsen, Anna Schultze, Frank Post, et al.
BMC Infectious Diseases|October 11, 2013
Non-AIDS defining cancers in the D:A:D Study--time trends and predictors of survival: a cohort studySigne W Worm, Mark Bower, Peter Reiss, et al.
Antiviral Therapy|December 1, 2005
Predictors of hypertension and changes of blood pressure in HIV-infected patientsRodolphe Thiébaut, Wafaa M El-Sadr, Nina Friis-Møller, et al.
The Journal of Infectious Diseases|September 11, 2019
Use of Contemporary Protease Inhibitors and Risk of Incident Chronic Kidney Disease in Persons With Human Immunodeficiency Virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) StudyLene Ryom, Jens Dilling Lundgren, Peter Reiss, et al.
Lancet (London, England)|April 5, 2008
Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration, Caroline A Sabin, Signe W Worm, et al.
The Journal of Infectious Diseases|July 9, 2020
The Impact of Immunosuppression on Chronic Kidney Disease in People Living With Human Immunodeficiency Virus: The D:A:D StudyLene Ryom, Jens D Lundgren, Peter Reiss, et al.
The New England Journal of Medicine|November 25, 2003
Combination antiretroviral therapy and the risk of myocardial infarctionNina Friis-Møller, Caroline A Sabin, Rainer Weber, et al.
Lancet (London, England)|July 22, 2014
Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaborationColette J Smith, Lene Ryom, Rainer Weber, et al.
BMC Infectious Diseases|September 3, 2025
No changes in weight, body composition or metabolic parameters after the switch to dolutegravir and lamivudine compared to continued treatment with dolutegravir, abacavir and lamivudine for virologically suppressed HIV infection (The AVERTAS trial)Karen Brorup Heje, Magnus Søltoft Lindhardt, Alessandra Meddis, et al.
Pageof 18

Showing results (121-130 of 171) with videos related to

Sort By:
Pageof 18
AIDS (London, England)|October 14, 2017
Abacavir use and risk of recurrent myocardial infarctionCaroline A Sabin, Lene Ryom, Antonella d'Arminio Monforte, et al.
Journal of the International AIDS Society|November 14, 2014
Major challenges in clinical management of TB/HIV co-infected patients in Eastern Europe compared with Western Europe and Latin AmericaAnne Marie Efsen, Anna Schultze, Frank Post, et al.
BMC Infectious Diseases|October 11, 2013
Non-AIDS defining cancers in the D:A:D Study--time trends and predictors of survival: a cohort studySigne W Worm, Mark Bower, Peter Reiss, et al.
Antiviral Therapy|December 1, 2005
Predictors of hypertension and changes of blood pressure in HIV-infected patientsRodolphe Thiébaut, Wafaa M El-Sadr, Nina Friis-Møller, et al.
The Journal of Infectious Diseases|September 11, 2019
Use of Contemporary Protease Inhibitors and Risk of Incident Chronic Kidney Disease in Persons With Human Immunodeficiency Virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) StudyLene Ryom, Jens Dilling Lundgren, Peter Reiss, et al.
Lancet (London, England)|April 5, 2008
Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration, Caroline A Sabin, Signe W Worm, et al.
The Journal of Infectious Diseases|July 9, 2020
The Impact of Immunosuppression on Chronic Kidney Disease in People Living With Human Immunodeficiency Virus: The D:A:D StudyLene Ryom, Jens D Lundgren, Peter Reiss, et al.
The New England Journal of Medicine|November 25, 2003
Combination antiretroviral therapy and the risk of myocardial infarctionNina Friis-Møller, Caroline A Sabin, Rainer Weber, et al.
Lancet (London, England)|July 22, 2014
Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaborationColette J Smith, Lene Ryom, Rainer Weber, et al.
BMC Infectious Diseases|September 3, 2025
No changes in weight, body composition or metabolic parameters after the switch to dolutegravir and lamivudine compared to continued treatment with dolutegravir, abacavir and lamivudine for virologically suppressed HIV infection (The AVERTAS trial)Karen Brorup Heje, Magnus Søltoft Lindhardt, Alessandra Meddis, et al.
Pageof 18